Current Stem Cell Research & Therapy - Volume 3, Issue 1, 2008

The aim of this review is to explore the idea that the glycosaminoglycan sugar heparan sulfate (HS), richly concentrated on the plasma membrane of all animal cells studied so far and a major component of extracellular matrices, is by virtue of its ability to modulate protein gradients and signal transduction, the master regulator of stem cell fate (and thus wound healing). Moreover, the interaction between HS and members of the TGF-β superfamily is emerging as a central tenet for stem cells. The potential significance of this interaction is best understood by examining both how HS modulates ligand interactions and stability, and how it maintains protein gradients with varying degrees of specificity. Importantly, HS also regulates the activity of numerous antagonists, thus underscoring its importance as a primary regulator of stem cell fate decisions.

Like other somatic stem cells, hematopoietic stem cells (HSC) have the ability to either self-renew or to differentiate. They are essentially required for the hematopoietic homeostasis. In this context HSC do not only need to replenish peripheral blood cells of all lineages, but also have to keep their pool relatively constant. Since disruption of the underlying control mechanisms can lead to degeneration or expansion of the HSC-pool as it occurs after irradiation or in leukemia, it is an important concern to unveil mechanisms that govern the decision of self-renewal versus differentiation in HSC-biology. There is good evidence that certain extrinsic cues provided in a special environment, the HSC-niches, essentially take part in regulating the HSC-pool in vivo and might also be involved in leukemogenesis. Apart from that, asymmetric cell divisions seem to be another control instance in hematopoietic homeostasis. It has been shown that siblings of primitive hematopoietic cells often adopt different cell fates, and very recently we identified four proteins that segregate asymmetrically in a proportion of dividing primitive hematopoietic cells. Whether asymmetric cell division participates in leukemogenesis, remains to be investigated. However, on the example of neural stem cells of the Drosophila larvae, the neuroblasts, asymmetrically segregating molecules have been identified, i.e. the tumor suppressor protein Brat and the transcription factor Prospero, that are required to suppress self-renewal in one of the arising daughter cells and whose loss of function results in tumor formation. These findings provide an attractive model of how defects in the process of asymmetric cell divisions might transform normal HSC/HPC into leukemic cells.

The concept of “field cancerization” describes the presence of histological abnormal tissue surrounding oral squamous cell carcinoma (OSCC). Molecular model of multistep carcinogenesis indicates that an accumulation of genetic alterations forms the basis for the OSCC progression with genetic heterogeneity. Furthermore, we reviewed cancer stem cell (CSC) model, which suggests functional heterogeneity in the tumor mass and current supporting evidence in OSCC. According to CSC model, prevention from carcinogen exposure and eliminating the particular CSCs instead of targeting tumor mass could help obtain a more long-lasting therapeutic effect.

Applications of regenerative medicine technology may offer new therapies for patients with injuries, end-stage organ failure, or other clinical problems. Currently, patients suffering from diseased and injured organs can be treated with transplanted organs. However, there is a shortage of donor organs that is worsening yearly as the population ages and new cases of organ failure increase. Scientists in the field of regenerative medicine and tissue engineering are now applying the principles of cell transplantation, material science, and bioengineering to construct biological substitutes that will restore and maintain normal function in diseased and injured tissues. The stem cell field is a rapidly advancing aspect of regenerative medicine as well, and new discoveries here create new options for this type of therapy. For example, therapeutic cloning, in which the nucleus from a donor cell is transferred into an enucleated oocyte in order to extract pluripotent embryonic stem cells from the resultant embryo, provides another source of cells for cell-based tissue engineering applications. While stem cells are still in the research phase, some therapies arising from tissue engineering endeavors have already entered the clinical setting, indicating that regenerative medicine holds promise for the future.

Mesenchymal stem cells (MSCs) from post-natal bone marrow possess tremendous potential for cell-mediated gene therapy in several disease processes, and recent reports have broadened the spectrum for therapeutic applications to cancer therapy. The evidence that sites of active tumorigenesis favor the homing of exogenous MSCs have support the rationale for developing engineered MSCs as a tool to track malignant tissues and deliver anticancer agents within the tumor microenvironment. Several reports have proven the efficiency of MSCs as cell carrier for in vivo delivery of various clinically relevant anticancer factors, including cytokines, interferon, pro-drugs or replicative adenovirus, and tumor growth inhibition following engraftment within or in the vicinity of tumor. The enthusiasm for MSCs is further reinforced by the striking observation that unmodified MSCs can exert antitumorigenic activity, and preliminary reports in immunocompetent animals have provided encouraging results for the use of MSCs in cancer immunotherapy. This review highlights recent works and potential clinical applications of MSCs in this field.

Mesenchymal stem cells (MSCs) represent a promising source of material for autologous cell transplantation therapies, in particular, their potential use for the treatment of damaged nervous tissue. Much of the work in this area has focused on the transplantation of MSCs into animal models of neurological disorders, including stroke and spinal cord injury. Although numerous studies have reported significant functional improvements in these systems, the exact mechanism( s) by which MSCs elicit recovery remains largely undefined. While it has been proposed that ‘trans’-differentiation and/or cell fusion events underly MSC-mediated neural repair, there is considerable doubt that the low frequency of these phenomena is sufficient to account for the observed levels of recovery. Furthermore, in vitro studies call into question the ability of MSCs to produce authentic neural derivatives. In this review we focus on recent evidence indicating that transplanted MSCs promote endogenous repair of neurologically damaged areas via the release of soluble trophic factors and cytokines. Through the modern analysis of MSC-conditioned media it is becoming possible to gain new insight into the release and interplay of these soluble factors and their neurogenic effects. Ultimately this understanding may lead to the rational design of new therapies for the treatment of neurological and neurodegenerative disorders.

Recently much effort has resulted in papers on how stem cells can be generated from adult tissues in mice, but the salamanders do this routinely. Salamanders can regenerate most of their body parts, such as limbs, eyes, jaw, brain (and spinal cord), heart, etc. Regeneration in salamanders starts by dedifferentiation of the terminally differentiated tissues at the site of injury. The dedifferentiated cells can then differentiate to reconstitute the lost tissues. This transdifferentiation in an adult animal is unprecedented among vertebrates and does not involve recruitment of stem cells. One of the ideas is that such reprogramming of terminally differentiated cells might involve mechanisms that are similar to the maintenance of embryonic stem cells. In the stem cell field much emphasis has been recently given to the reprogramming of adult cells (such as skin fibroblasts) to revert to ES or pluripotent stem cells. It is our conviction that generation of dedifferentiated cells in salamanders and stem cells, such as the ones seen in repair in mammals share molecular signatures. This mini review will discuss these issues and ideas that could unite the stem cell biology with the classical regeneration models.

Breast cancer is a first magnitude problem of public health worldwide. There is increasing evidence that this cancer is originated in and maintained by a small population of undifferentiated cells with self-renewal properties. This small population generates a more differentiated pool of cells which represents the main mass of the tumor, resembling the hierarchical tissue organization of the normal breast. These cancer stem cells seem to share a similar phenotype with their normal counterparts but they display dysfunctional patterns of proliferation and differentiation, and they no longer respond to normal physiological controls that ensure a balanced cellular turnover. The origin of these cancer stem cells is controversial; it is not well known if they are originated from normal stem cells or from more differentiated progenitors where a de novo stem cell program is activated by the oncogenic insult. Here we review the origin of breast cancer stem cells and their role in the pathogenesis of cancer development, together with their implications in breast cancer progression, treatment and prognosis.

Recently considerable interests have been roused in nuclear reprogramming by somatic cell nuclear transfer using an egg cytoplasm and/or by other means, such as fusion, cell extracts treatment and genes transfections. However, the very mechanism of reprogramming still remains elusive. Epigenetic modifications, which play a significant role in normal mammalian development in vivo is also involved in the process of reprogramming in vitro. The latter shares some of the other features observed in nuclear reprogramming in vivo. In this review, we discuss the main epigenetic changes involved in nuclear reprogramming and currently available approaches to achieve nuclear reprogramming in vitro and its future prospects.